FindMyKOL
Clinical trialNCT04764383WithdrawnPhase 2Interventional

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383 is a phase 2 interventional trial sponsored by University of Miami. As of 21 Nov 2026, it was withdrawn. It studies Histidine, Lodosyn and Placebo in Multiple Sclerosis. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 1 Jan 2022 and a primary completion date of 30 Oct 2022.

SponsorUniversity of Miami →Enrollment0Multiple Sclerosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04764383
FieldValue
Registry IDNCT04764383
StatusWithdrawn
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of Miami
Enrollment0
Registered sites1
Countries1
ConditionsMultiple Sclerosis
DrugsHistidine, Lodosyn and Placebo
Start1 Jan 2022
Primary completion30 Oct 2022
Study completion30 Oct 2022
Last update posted29 Jul 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to identify a way to improve the feeling of exhaustion that patients might experience because of Multiple Sclerosis (MS).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • University of Miami

    Miami

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HistidineLodosynPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04764383

Each answer restates registry values shown on this page.

What is NCT04764383?

NCT04764383 is a phase 2 interventional trial sponsored by University of Miami. It studies Histidine, Lodosyn and Placebo in Multiple Sclerosis.

Who leads NCT04764383?

The registry names Kottil Rammohan, MD (principal investigator, University of Miami) as the overall official.

Where does NCT04764383 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04764383 study?

The registered drug and biological interventions are Histidine, Lodosyn and Placebo.

When did NCT04764383 end?

The registry lists a primary completion date of 30 Oct 2022 and a study completion date of 30 Oct 2022. The sponsor last updated the record on 29 Jul 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.